Quick Answer
Royalty Pharma plc reported Net Income of $770.95 million for fiscal year 2025.
Royalty Pharma plc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $770.95M | -10.2% |
| 2024 | $858.98M | -24.3% |
| 2023 | $1.13B | +2549.5% |
| 2022 | $42.83M | -93.1% |
| 2021 | $619.73M | -36.4% |
| 2020 | $975.04M | -58.5% |
| 2019 | $2.35B | +70.5% |
| 2018 | $1.38B | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $288.22M | -47.0% | +855.1% |
| June 30, 2025 | $30.18M | -70.4% | -87.3% |
| March 31, 2025 | $238.35M | +4888.5% | -56.2% |
| September 30, 2024 | $543.99M | +654.3% | +433.3% |
| June 30, 2024 | $102.00M | -55.2% | +2034.9% |
| March 31, 2024 | $4.78M | -98.6% | -93.4% |
| September 30, 2023 | $72.11M | -49.4% | -68.3% |
| June 30, 2023 | $227.62M | -25.2% | -33.2% |
- Royalty Pharma plc showed a decrease of -10.2% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Royalty Pharma plc’s net income has declined by 44.0% (from $1.38 billion to $770.95 million).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: